跳至主要内容
临床试验/CTRI/2025/04/084357
CTRI/2025/04/084357招募中不适用

Prospective clinical study evaluating contemporary MANTA® safety outcomes in India (MANTA® Safety Study in India)

Teleflex Medical India Private Limited6 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2025年4月16日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
59
试验地点
6
主要终点
VCD Large Bore Access-site Related VARC-3 Major & Minor Vascular complications through discharge following TAVR/EVAR/TEVAR procedure (adapted from VARC-3 Criteria 1).

研究概览

简要总结

This is a prospective, multicentre, observational, single-arm study to examine and collect data on safety outcomes of MANTA® large bore closure device in patients undergoing standard of care (SOC) Transcatheter aortic valve replacement (TAVR)/ Endovascular aneurysm repair (EVAR)/ Thoracic Endovascular Aortic Repair (TEVAR) procedures in femoral arterial access sites in India. The patients will be followed up for a period of 1 month. The primary objective is to estimate the percentage of subjects with one or more VARC-3 major and minor vascular complications through discharge following TAVR/EVAR/TEVAR procedure.

研究设计

研究类型
Observational

入排标准

年龄范围
21.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • 1.Candidate meets criteria for on-label use of MANTA® VCD as specified in MANTA® VCD Instructions for Use (IFU), as per judgement of the investigator.
  • 2.Age 21 years & above.

排除标准

  • Before the procedure- 1.Unable or unwilling to give informed consent or unwilling to complete follow-up assessments.
  • 2.Severe calcification of the access vessel.
  • 3.Severe peripheral artery disease.
  • 4.Marked tortuosity of the femoral or iliac artery.
  • 5.Patients who cannot be anti-coagulated for the procedure 6.Marked obesity or cachexia (BMI above 40 or below 20).
  • During the TAVR/EVAR/TEVAR procedure- 7.Puncture in the origin of the profundal femoral artery, above the inguinal ligament, or above the most inferior border of the epigastric artery (IEA).
  • 8.Sheath insertion in the vessel other than the femoral artery.
  • 9.Blood Pressure above 180 mmHg.

结局指标

主要结局

VCD Large Bore Access-site Related VARC-3 Major & Minor Vascular complications through discharge following TAVR/EVAR/TEVAR procedure (adapted from VARC-3 Criteria 1).

时间窗: 1 Month

次要结局

  • Additional interventions required at large bore access site to address bleeding or other large bore access site complications (e.g., bare, or(covered stent, or surgical repair) through discharge following TAVR/EVAR/TEVAR)
  • VCD Large Bore Access-site Related VARC- 3 Major & Minor Vascular complications within 30 days of TAVR/EVAR/TEVAR(procedure (adapted from VARC-3 Criteria1); reported by Investigators.)

研究者

发起方
Teleflex Medical India Private Limited
申办方类型
Other [Medical Device]
责任方
Principal Investigator
主要研究者

Dr Deepak Davidson

Caritas Hospital & Institute of Health Sciences

研究点 (6)

Loading locations...

相似试验